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Background: Platelet activation with subsequent neutrophilic adherence to the vasculature
initiates ischemia-reperfusion injury. We hypothesized that higher plasma P-selectin levels
reflecting platelet activation would therefore be associated with primary graft dysfunction (PGD)
after lung transplantation.
Methods: In a prospective, multicenter cohort study of 376 patients who had undergone lung
transplantation between 2002 and 2007, we measured soluble P-selectin levels before lung
transplantation and at 6 and 24 h after lung reperfusion in 20 patients with grade III PGD
(PaO2/fraction of inspired oxygen, < 200 mm Hg [with alveolar infiltrates seen on chest
radiographs]) at 72 h after transplantation and 61 control subjects without PGD.
Results: Higher postoperative soluble P-selectin levels were associated with an increased risk of
PGD at 72 h after transplantation (odds ratio [OR] per 1 natural log increase in soluble P-selectin
at 6 h after lung allograft reperfusion, 3.5; 95% confidence interval [CI], 1.01 to 11.8; p  0.048)
and at 24 h after lung allograft reperfusion (OR, 4.8; 95% CI, 1.4 to 16.1; p  0.01). Higher
preoperative mean pulmonary artery pressure and the use of cardiopulmonary bypass were also
associated with an increased risk of PGD.
Conclusion: Higher postoperative soluble P-selectin levels were associated with an increased risk
of PGD at 72 h following lung transplantation. (CHEST 2009; 136:237–244)
Abbreviations: ALI  acute lung injury; CI confidence interval; CPB cardiopulmonary bypass; Fio2  fraction of
inspired oxygen; IQR interquartile range; mPAP mean pulmonary artery pressure; OR odds ratio; PGD
primary graft dysfunction
P rimary graft dysfunction (PGD) is a form of acutelung injury (ALI) occurring immediately after
lung transplantation due to ischemia-reperfusion in-
jury.1–4 The incidence of PGD ranges from 10 to
25%, and PGD is the leading cause of early post-
transplantation morbidity and mortality.1–3,5–7 The
risk factors for PGD are varied, involving the donor,
recipient, and the processes of cold ischemia and
reperfusion of the lung allografts.8,9
Prior studies10–13 have demonstrated that the adhe-
sion of neutrophils to the pulmonary vascular endothe-
lium, diapedesis, and infiltration into the vessel wall are
key initial steps in ALI and PGD, leading to the
capillary leak that characterizes these syndromes. Acti-
vated platelets play an integral role in the tethering and
activation of neutrophils with eventual firm adherence
to the vascular wall and transit to the interstitial and
alveolar spaces. P-selectin is mobilized to the platelet
surface from  granules and to the endothelial cell
membrane from Weibel-Palade bodies and serves as a
receptor to a variety of ligands before being shed in the
plasma in soluble form.14 Although soluble P-selectin
therefore may be of platelet or endothelial origin, it is
considered a reliable and valid measure of platelet
activation.15,16 Animal models of ALI show elevations
in soluble P-selectin levels,11 suggesting that platelet
activation is present. P-selectin may have mechanistic
importance in PGD as well because P-selectin block-
ade (or P-selectin knockout) protected the lung allograft
after ischemia and reperfusion in a mouse model.17
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We have previously shown18 that soluble P-selectin
levels, CD40 ligand levels, and platelet-leukocyte ag-
gregates (the most sensitive measure of platelet activa-
tion) increase in parallel after lung transplantation
without cardiopulmonary bypass (CPB) compared to
nontransplant thoracic surgery, indicating that soluble
P-selectin in these patients is most likely shed from
platelet sources in response to lung implantation. How-
ever, to our knowledge, no previous studies have
addressed the relationship between platelet activity and
PGD. In the current study, we hypothesized that
platelet activation, as measured by increased soluble
P-selectin levels, would be associated with a higher risk
of PGD in lung transplantation recipients.
Materials and Materials
We performed a case-control study nested in a prospective
cohort of 376 patients undergoing a first lung transplantation at
seven centers in the United States (see Appendix for institutions
and investigators). The study sample consisted of 20 randomly
selected case patients with PGD grade III and 61 control subjects
without PGD (PGD grade 0) enrolled between 2002 and 2007
with sufficient plasma. PGD case patients had diffuse alveolar
infiltrates involving the lung allografts and, in the case of a
single lung transplant, sparing the native lung, as seen on chest
radiographs; Pao2/fraction of inspired oxygen (Fio2) ratio of
 200 mm Hg; and no other secondary cause of graft dysfunction
identified, all at 72 h after transplantation. This definition has
been validated previously.1,2,4,7 Control subjects were patients
from the cohort with clear lung allografts as determined by chest
radiography (PGD grade 0) at 72 h after transplantation (see
online supplement for details).
Informed consent for this study was obtained prior to organ
transplantation. Blood samples were obtained in citrated tubes
(Vacutainer; Becton Dickinson; Franklin Lakes, NJ) before trans-
plantation, and at 6 h and 24 h after reperfusion of the lung
allograft. Samples were centrifuged within 30 min of collection,
and plasma samples were stored at 80°C. Clinical variables
were categorized and defined using methods published previously.3
Soluble P-selectin levels were measured in a central laboratory
with an ultrasensitive, solid-phase sandwich, enzyme-linked im-
munosorbent assay (R&D Systems; Minneapolis, MN) [see on-
line supplement for details].
Statistical Analysis
Data were summarized as the mean  SD and median (inter-
quartile range [IQR]), as appropriate. Unpaired t tests, rank sum
tests, signed rank tests, and 2 or Fisher exact tests were used to
compare PGD case patients with non-PGD control subjects.
Correlations were assessed using Spearman rank correlation
coefficients.
Bivariate and multivariate logistic regression models were used
to assess the relationship between soluble P-selectin levels at
baseline, 6 h, and 24 h postoperatively and the occurrence of
PGD at 72 h after lung transplantation. Included in the multi-
variate analysis were potential confounding variables with p
values  0.20 in bivariate analyses. Potential confounders were
included in the models one at a time; significant confounding was
indicated by a change in the coefficient of the term for soluble
P-selectin  20%. Mean pulmonary artery pressure (mPAP) at
anesthesia induction was considered in quartiles with indicator
variables in the regression models; missing data were coded as
such in this analysis. Soluble P-selectin levels were log trans-
formed for the regression analysis. Power calculations are pro-
vided in the online supplement.
All statistical comparisons were performed using a statistical
software package (Stata, version 10.0; Stata Corp; College Sta-
tion, TX). This research protocol was approved by the institu-
tional review boards at each of the participating centers.
Results
There were 81 patients in the study sample (Table
1). The mean age of the patients was 53 12 years,
33 patients (41%) were women, and 72 patients
(89%) were non-Hispanic white. Most patients had
undergone lung transplantation for COPD, and 25
patients (31%) received CPB.
Soluble P-selectin levels before lung transplanta-
tion and at 6 and 24 h after reperfusion of the lung
allografts are shown in Figure 1. One patient had a
missing preoperative P-selectin level, two had miss-
ing levels at 6 h, and one had a missing level at 24 h.
In the entire study sample, median soluble P-selectin
levels significantly increased from baseline (61
ng/mL [IQR, 47 to 80 ng/mL]) to 6 h (74 ng/mL
[IQR, 50 to 111 ng/mL], p 0.001 vs baseline) and
to 24 h (69 ng/mL [IQR, 50 to 99 ng/mL], p 0.003
vs baseline) after reperfusion.
Among those PGD and non-PGD patients who
did not receive CPB during the transplantation
procedure (n 56), there was still a significant
median increase in soluble P-selectin levels from
baseline (60 ng/mL [IQR, 46 to 76 ng/mL]) to 6 h (69
ng/mL [IQR, 45 to 104 ng/mL], p 0.004 vs base-
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line) and possibly to 24 h (66 ng/mL [IQR, 45 to 95
ng/mL], p 0.09 vs baseline) after reperfusion. Fo-
cusing only on the non-PGD control group (with or
without CPB) [n 61], we again found that median
soluble P-selectin levels increased from baseline (60
ng/mL [IQR, 46 to 79 ng/mL]) to 6 h (70 ng/mL
[IQR, 46 to 109 ng/mL], p 0.002 vs baseline) and
possibly to 24 h (63 ng/mL [IQR, 45 to 97 ng/mL],
p  0.07 vs baseline) after reperfusion.
Patients with diffuse parenchymal lung disease in
the entire study sample may have had higher median
soluble P-selectin levels before transplantation than
patients with COPD (64 ng/mL [IQR, 59 to 87
ng/mL] vs 56 ng/mL [IQR, 38 to 69 ng/mL], respec-
tively; p 0.06) Although mPAP at anesthesia in-
duction for lung transplantation was not associated
with soluble P-selectin levels at baseline in the entire
study sample (r  0.02; p 0.93), there were signif-
icant direct associations between mPAP at anesthesia
induction and soluble P-selectin levels at 6 and 24 h
after lung transplantation in the entire study sample
and in those who did not receive CPB (Fig 2, 3). In




























Figure 1. Box-and-whisker plots of soluble P-selectin levels
preoperatively and at 6 and 24 h after lung allograft reperfusion.
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Figure 2. Scatterplots of soluble P-selectin levels at 6 h after
lung allograft reperfusion vs mPAP at induction. A: all patients
(n  59). B: patients not receiving CPB (n 44).
Table 1—Characteristics of the Study Sample
Characteristics No. Data
Recipient variables
Age, yr 81 53  12
Female sex 81 33 (41)
Race/ethnicity 81






Diffuse parenchymal lung disease 28 (35)
Cystic fibrosis 10 (12)
Other 6 (7)
Donor variables
Age, yr 81 31  14
Female sex 81 34 (42)
Race/ethnicity 81





Bilateral transplant 81 50 (62)
Use of CPB 81 25 (31)
mPAP at induction, mm Hg 61 29  12
Ischemic time, min 77 293 (240–352)
Packed RBCs during first 24 h, mL 81 250 (0–1,000)
Platelets during first 24 h, mL 81 0 (0–0)
Fresh frozen plasma during first 24 h, mL 81 0 (0–450)
Values are given as the mean  SD, No. (%), or median (IQR).
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associations between CPB time and soluble P-selectin
levels at any time point (data not shown).
We then compared PGD case patients to non-
PGD control subjects (Table 2). PGD case patients
tended to be younger than control subjects; however,
there were no sex differences between the groups.
PGD case patients were less likely to be non-
Hispanic white and more likely to be black than
control subjects. Case patients with PGD were more
likely to have undergone transplantation for diffuse
parenchymal lung disease than for COPD. PGD case
patients had higher mPAP levels at induction, had
more frequently used CPB, and had required trans-
fusion of more blood products during transplantation
and during the first 24 h postoperatively.
Case patients with PGD had median soluble P-
selectin levels at baseline that were similar to those
of control subjects without PGD (64 ng/mL [IQR, 56
to 83 ng/mL] vs 60 ng/mL [IQR, 46 to 79 ng/mL],
respectively; p  0.50) [Fig 4]. However, case pa-
tients with PGD had higher median soluble P-selectin
levels than non-PGD control subjects at 6 h (97 ng/mL
[IQR, 73 to 112 ng/mL] vs 70 ng/mL [IQR, 46 to 109
ng/mL], respectively; p 0.03) and at 24 h (91 ng/mL
[IQR, 74 to 118 ng/mL] vs 63 ng/mL [IQR, 45 to 97
ng/mL], respectively; p 0.006) after lung reperfu-
sion.
Higher soluble P-selectin levels at 6 h after lung
allograft reperfusion were associated with an in-
creased risk of PGD (odds ratio [OR] per 1 natural
log increase in soluble P-selectin level, 3.5; 95%
confidence interval [CI], 1.01 to 11.8; p 0.048), as
they were at 24 h after lung reperfusion (OR per 1
natural log increase in soluble P-selectin level, 4.8;
95% CI, 1.4 to 16.1; p 0.01) [Table 3]. Adjustment
for a variety of variables, including sex, race, or
pulmonary diagnosis, did not affect the results. Sim-
ilarly, there was no change in the findings after
adjustment for the use of blood products, such as
packed RBCs, platelets, or fresh frozen plasma. The
associations between soluble P-selectin levels and
PGD case status seemed to be explained in part by
the use of CPB because adjustment for this factor
significantly reduced the effect estimates of soluble
P-selectin levels.
Discussion
PGD contributes significantly to overall morbidity
and is the major cause of early death following lung
transplantation. We have shown that higher soluble
P-selectin levels were associated with the occurrence
of PGD in this case-control study nested within a
large multicenter cohort of patients undergoing lung
transplantation. Although increased mPAP and CPB
are traditional risk factors for PGD (and were risk
factors in our study), we have shown that increased
soluble P-selectin levels and platelet activation may
explain the mechanism of these associations. We
have previously characterized PGD in terms of coagu-
lation/fibrinolysis, endothelial dysfunction, inflamma-
tion, and oxidative stress.19–21 However, these are the
first data showing the importance of increased platelet
activation in patients with PGD following human lung
transplantation.
Platelets contribute to the course of ischemia-
reperfusion injury in patients who have undergone
transplants of other solid organs, such as the liver22;
however, there is less known about this process in
the lung.23 Okada et al24 showed that the accumula-
tion of platelets in preserved and transplanted rat
lungs was associated with the degree of reperfusion
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Figure 3. Scatterplots of soluble P-selectin levels at 24 h after
lung allograft reperfusion vs mPAP at induction. A: all patients
(n  60). B: patients not receiving CPB (n 44).
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congestion. Other studies17,25 of animal models of
ischemia-reperfusion injury and ALI have not only
documented platelet-mediated leukocyte infiltration
in the lungs, but also specifically identified platelet-
derived P-selectin as the key molecule in this pro-
cess. One study17 utilized a rat model of orthotopic
left lung transplantation after 6 h of hypothermic
preservation. The administration of blocking anti-P-
selectin antibody before reperfusion reduced pulmo-
nary vascular resistance, increased Pao2, and improved
survival. P-selectin knockout mice subjected to 30
min of pulmonary ischemia followed by reperfu-
sion also showed significant reductions in neutro-
phil infiltration, increases in Pao2, and prolonged
survival compared to wild-type mice. A model of
lung ischemia-reperfusion in rabbits confirmed
the rolling and adherence of platelets mediated by
platelet P-selectin in the pulmonary vasculature
after reperfusion.25
Zarbock et al26 have shown that platelets play an
important role in the accumulation of neutrophils in
the intravascular, interstitial, and intraalveolar spaces
of the lung in ALI. Platelet depletion in this model
prevented abnormalities in gas exchange, accumula-
tion of neutrophils in all three compartments, and
protein leak. Antibodies against P-selectin prevented
the formation of circulating platelet-neutrophil ag-
gregates, decreased neutrophils in BAL fluid, im-
proved the Pao2/Fio2 ratio, and prolonged survival
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Figure 4. Box-and-whisker plots of soluble P-selectin levels
for PGD case patients and control subjects preoperatively and
at 6 and 24 h after lung allograft reperfusion. Horizontal
line  median; box  25th and 75th percentiles; whiskers 
adjacent values.
Table 2—Characteristics of PGD Case Patients and Control Subjects
Characteristics No. Case Patients (n  20) Control Subjects (n  61) p Value
Recipient variables
Age, yr 81 49  14 54  12 0.18
Female sex 81 8 (40) 25 (42) 0.94
Race/ethnicity 81 0.02
Non-Hispanic white 15 (75) 57 (93)
Black 5 (25) 3 (5)
Hispanic 1 (2)
Diagnosis 81 0.03
COPD 5 (25) 32 (52)
Diffuse parenchymal lung disease 12 (60) 16 (26)
Cystic fibrosis 1 (5) 9 (15)
Other 2 (10) 4 (7)
Donor variables
Age, yr 81 30  13 32  14 0.69
Female sex 81 8 (40) 25 (41) 0.94
Race/ethnicity 81 0.30
Non-Hispanic white 18 (90) 43 (71)
Black 8 (13)
Hispanic 2 (10) 8 (13)
Other 2 (3)
Surgical variables
Bilateral transplant 81 13 (65) 37 (61) 0.73
Use of CPB 81 14 (70) 11 (18)  0.001
mPAP at induction, mm Hg 61 40  14 25  9  0.001
Ischemic time, min 77 286 (257–375) 300 (235–352) 0.50
Packed RBCs during first 24 h, mL 81 875 (0–1,500) 250 (0–750) 0.05
Platelets during first 24 h, mL 81 0 (0–622) 0 (0–0)  0.001
Fresh frozen plasma during first 24 h, mL 81 363 (0–1,053) 0 (0–0) 0.002
Values are given as the mean  SD, No. (%), or median (IQR), unless otherwise indicated.
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and reconstituted with bone marrow from P-selectin
knockout mice (thus permitting endothelial P-selectin
but not megakaryocyte P-selectin expression) dem-
onstrated better gas exchange and decreased neutro-
phil accumulation in the intravascular, interstitial,
and intraalveolar spaces of the lung compared to
wild-type mice with intact bone marrow. Another
study27 showed that platelet P-selectin was critical to
the proinflammatory phenotype of endothelial dys-
function induced by high-tidal volume ventilation.
We have previously shown18 that human lung
transplantation itself is associated with platelet acti-
vation, even in the absence of traditional risk factors
such as significant pulmonary hypertension and
CPB. Our prospective cohort study18 of patients
undergoing lung transplantation without CPB and
patients undergoing nontransplantation thoracic sur-
gery showed significant increases in levels of soluble
P-selectin, CD40 ligand, and circulating platelet-
monocyte conjugates in the lung transplantation
patients compared to the thoracic surgery patients.
Interestingly, the increases in these platelet markers
in the lung transplantation recipients were associated
with decreases in platelet count, suggesting that
more platelet activation was associated with greater
platelet consumption or trapping, presumably in the
lung allografts. These findings suggest that the trans-
plantation procedure leads to platelet activation,
even in the absence of CPB. Importantly, the per-
sistence of the association between soluble P-selectin
levels and PGD in the current study, despite adjust-
ment for the use of blood products, indicates that
transfusion does not account for our findings.
Colombat et al28 have confirmed that platelet
trapping occurs in the newly perfused lung allografts
after human lung transplantation and has a signifi-
cant impact on oxygenation and allograft function.
These investigators performed lung sampling 15 to
30 min after reperfusion. Platelet aggregation in
the venular plexus was more prominent in the lung
transplantation samples than in samples of lung
tissue from control subjects. The finding of P-
selectin-stained platelets in the vascular lumen
after lung transplantation was associated with a
longer duration of mechanical ventilation, lower
Pao2/Fio2 ratio, and pulmonary edema, as shown
by chest radiography.
The association between pulmonary hypertension
and PGD is complex and poorly understood. Some
studies3 have suggested that only the diagnosis of
pulmonary arterial hypertension itself increases the
risk of PGD; other studies29 suggest that each higher
increment of pulmonary artery pressure (from any
underlying lung disease) translates to an increase in
risk of PGD. In addition, because patients with
significant pulmonary hypertension require CPB to
undergo the transplantation procedure, it is difficult
to tease out the respective causal roles. We showed
that higher mPAP at induction was associated with
higher soluble P-selectin levels both at 6 and 24 h
after lung transplantation. This association appeared
to persist even in those patients who did not require
CPB, suggesting that preoperative pulmonary vascu-
lar disease results in platelet activation after lung
transplantation independent of CPB. It is possible
that long-standing pulmonary hypertension or
right ventricular dysfunction may result in platelet
defects leading to heightened susceptibility to an acti-
vated pulmonary vascular endothelium after transplan-
tation. The compete lack of association between mPAP
and soluble P-selectin levels at baseline suggests that
some trigger is necessary to unmask this process.
Table 3—Logistic Regression Models for the Association of P-selectin Levels at 6 and 24 h With PGD
Variables
OR for PGD per
1 ln Increase in
P-selectin at 6 h
After Reperfusion 95% CI p Value
OR for PGD per
1 ln Increase in
P-selectin at 24 h
After Reperfusion 95% CI p Value
Unadjusted 3.5 1.01–11.8 0.048 4.8 1.4–16.1 0.01
Adjusted for
Recipient age 2.9 0.8–10.9 0.11 4.4 1.2–16.0 0.02
Recipient sex 4.8 1.4–16.7 0.01 4.8 1.4–16.7 0.01
Recipient diagnosis 4.8 1.1–20.6 0.04 5.1 1.4–19.2 0.02
Recipient race/ethnicity 4.1 1.1–14.7 0.03 6.9 1.8–27.3 0.005
mPAP at induction 3.8 1.2–18.7 0.07 4.8 1.2–18.7 0.025
Bilateral transplant 3.5 1.0–12.0 0.05 4.9 1.4–17.1 0.01
Use of CPB 2.1 0.5–8.8 0.29 2.9 0.7–11.3 0.13
Ischemic time 3.2 0.9–11.5 0.07 4.2 1.2–14.8 0.03
Packed RBCs during first 24 h 3.7 1.0–13.2 0.04 5.1 1.5–17.6 0.01
Platelets during first 24 h 4.9 1.4–16.9 0.06 4.9 1.4–16.9 0.01
Fresh frozen plasma during first 24 h 2.9 0.8–10.4 0.10 4.5 1.3–15.6 0.02
ln  natural log.
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There are several limitations to our study. First,
PGD encompasses a spectrum of injury; we studied
the extremes of this spectrum. Future prospective
cohort studies should include patients with PGD
grades I and II. Second, we intentionally did not match
the control subjects to case patients in terms of pulmo-
nary diagnosis or CPB use because such matching can
introduce bias and actually decrease efficiency in cer-
tain situations. We did however adjust (or “control”) for
differences in baseline covariates between case patients
and control subjects in multivariate analyses, which is
the preferable methodological approach in a study such
as ours. Of course, the possibility of unmeasured or
residual confounding exists.
In this study, we have provided the first evidence
that elevated levels of soluble P-selectin are associ-
ated with PGD in human lung transplantation. These
data and the strong body of evidence from animal
models demonstrating that interference with P-
selectin leads to attenuation of ischemia-reperfusion
injury make targeting platelet activation a promising
therapeutic approach in humans undergoing lung
transplantation.
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